GLP-1 drugs expand from diabetes to obesity treatment in US

GLP‑1 receptor agonists, first approved to improve glycemic control in patients with type 2 diabetes, have rapidly become a cornerstone of obesity treatment in the United States. Since the 2021 FDA approval of semaglutide for chronic weight management under the brand name Wegovy, and the subsequent clearance of tirzepatide (Mounjaro) for the same indication, prescriptions for these agents have surged, with sales projected to exceed $30 billion by 2027. The drugs’ ability to produce significant, sustained weight loss—often 15 percent or more of body weight—has prompted clinicians to incorporate them into standard care pathways for both metabolic disease and weight‑related comorbidities such as hypertension and dyslipidemia.

The expanding use of GLP‑1 therapies is reshaping reimbursement policies, supply chains, and clinical practice. Major insurers have begun to cover the medications for obesity, though prior‑authorization requirements and high out‑of‑pocket costs remain barriers for many patients. Pharmaceutical manufacturers report periodic shortages driven by demand that outpaces production capacity. Health‑system analysts note that the broader adoption of GLP‑1 drugs may reduce long‑term costs associated with obesity‑related complications, while also raising concerns about equitable access and the need for comprehensive lifestyle support. As the market matures, regulators and providers are monitoring safety data, cost‑effectiveness, and the potential for off‑label use to ensure that the therapeutic benefits of GLP‑1 agents are realized across the population.